The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 07, 2012
Filed:
May. 02, 2006
Peter W. Laird, South Pasadena, CA (US);
Kimberly D. Siegmund, San Marino, CA (US);
Mihaela Campan, Los Angeles, CA (US);
Daniel J. Weisenberger, Playa del Rey, CA (US);
Tiffany I. Long, Chino, CA (US);
Peter W. Laird, South Pasadena, CA (US);
Kimberly D. Siegmund, San Marino, CA (US);
Mihaela Campan, Los Angeles, CA (US);
Daniel J. Weisenberger, Playa del Rey, CA (US);
Tiffany I. Long, Chino, CA (US);
University of Southern California USC Stevens Center for Innovation, Los Angeles, CA (US);
Abstract
Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use).